Q3 saw 13.5% sales growth and improved EBITDA, driven by the Selteka acquisition and EMS strength, while Enedo continued restructuring with significant one-off costs. Break-even for Enedo is targeted for Q1 next year, and full recovery is expected as restructuring costs subside.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.